4Boomsma F, van den Meiracker AH. Plasma A-and B-type natriuretic peptides; physiology, methodology and clinical use [J]. Cardiovase Res,2001,51(3) :442-449.
5Publication Committee for the VMAC investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial [J]. JAMA,2002,287(12) :1531-1540.
6Colucci WS, Elkayam U, Horton DP, et at. Intravenous nesiritide, a natriuretie peptide, in the treatment of decompensated congestive heart failure[J]. N Engl J Med, 2000, 343(4) : 246-253.
7Cataliotti A. Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure[J]. Circulation, 2004,109(13) : 1680- 1685.
8Kemperman H, van den Berg M, Kirkels H, et al. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device[J] Clin Chem, 2004,50 (9): 1670-1672.
9Kapoun AM, Liang F, O' Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factorbeta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation[J]. Circ Res, 2004,94(4) : 453-461.
2Publication Committee for the VMAC Investigators(Vasodilatation in the Management of Acute CHF).Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial,2002(12).
3Yancy CW;Saltzberg MT;Berkowitz RL.Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial)[J],2004(05).
4Burger AJ;Horton DP;LeJemtel T.Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure:the PRECEDENT study[J],2002(06).
3Mc Cullough PA,Philbin EF,Spetus JA,et al. Confirmation of a heart failure epidemic.-findings from the resource utilization among congestive heart failure (REACH) study. J Am Coll Cardiol,2003,39(1) :60-69.
4Nakamura M, Arakawa N, Yoshida H, et al Vasodilatory effects of B-type natrluretic peptide are inpaired in patients with chronic heart failure. Am Heart J, 1998,135 : 414-420.
5Azzazy HM, Christenson RH. B-type natriuretic peptide: physiologic role and assay characteristics. Heart Fail Rev, 2003,8(4) :315-320.
7Robeo L, Serge N, Inder A, et al.Effects of Valsartanon circulating brain natriuretic peptide an norepingphrineinsy NptoNatic chronic heart failure[J]. Circulation,2002,106 (19): 2454-2458.
